Cargando...

Response to Lapatinib-Capecitabine combination in a young patient with recurrent HER2-positive breast cancer refractory to two lines of therapy with anti-HER2 drugs

HER2-positive breast cancer is an aggressive tumour that affects approximately one in five breast cancer women. Clinical studies have shown that HER2-positive cancer have different characteristics from other mammary tumors: a more rapid progression of the disease, an earlier age of onset (women of c...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Clementina Savastano, Fortuna Lombardi
Formato: Artigo
Idioma:Inglês
Publicado: AboutScience Srl 2018-10-01
Series:AboutOpen
Assuntos:
Acceso en liña:https://journals.aboutscience.eu/index.php/aboutopen/article/view/135
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!